Pakistan's drug regulatory authorities recall a batch of Injection Rhophylac 300 due to sterility concerns, affecting health safety.
The Directorate of Drugs Control (DDC), Punjab has issued a Class-I recall for a specific batch of Injection Rhophylac 300 (Human Anti-D Immunoglobulin) following laboratory findings that indicated substandard quality. This decision comes after the product failed a sterility test, raising serious health safety concerns.
The recall affects only one particular batch number and is being implemented to ensure patient safety. Health officials are advising healthcare providers and patients who received this specific batch of Rhophylac 300 to immediately stop using it and dispose of any remaining quantities safely.
This precautionary measure underscores the importance of stringent quality control in pharmaceutical products, especially those used for immunization purposes. The DDC is collaborating with relevant authorities to trace all instances where this substandard batch was distributed and ensure that affected individuals are informed about the recall.
Healthcare professionals across Punjab have been advised to follow up on patients who received the recalled Rhophylac 300 injection, monitoring them closely for any adverse reactions or symptoms. The DDC is also working with manufacturers to investigate the root cause of this substandard batch and implement corrective actions to prevent similar incidents in the future.
Consumers are encouraged to keep an eye out for further updates from health authorities regarding this recall and to seek medical advice if they have concerns about their recent immunization history.
